Reason for request
Extension of indication
Clinical Benefit
| Substantial |
The actual benefit of CERUBIDINE 20 mg is substantial, as part of a combination chemotherapy regimen, in the treatment of acute lymphoblastic leukaemia and acute myeloblastic leukaemia in children. |
Clinical Added Value
| no clinical added value |
CERUBIDINE 20 mg does not provide any improvement in actual benefit (level V, non-existent) in the treatment of acute lymphoblastic and myeloblastic leukaemia in children. |
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
A1ZX3UP1hms2CF25
